NHS England – Federated Data Platform: https://www.gov.uk/government/news/the-nhs-federated-data-platform-the-importance-of-building-bridges-with-the-public
The National Health Service (NHS) in England is in the process of procuring a Federated Data Platform (FDP), aiming to streamline IT systems and improve healthcare delivery. However, the initiative has come under scrutiny, particularly around ethics, privacy, and commercial involvement. The National Data Guardian’s role is to offer advice and ensure that the NHS maintains public trust, especially concerning data management.
Public concerns mainly revolve around commercial interest in NHS data. Research indicates that the public is generally open to commercial involvement if conditions such as transparent communication, public benefit, and adequate safeguards against misuse are met. Previous initiatives like the General Practice Data for Planning and Research (GPDPR) serve as cautionary tales. Lack of communication led to misinformation and resulted in a significant number of people opting out of data-sharing, negatively affecting health research and planning.
To avoid repeating past mistakes, the National Data Guardian advocates for meaningful and open dialogue between NHS England and the public. They outline three key focus areas:
- Value to Patients and the NHS: Clearly communicate the FDP’s purpose and benefits. Answer critical questions like the scope of the program, public choice in data sharing, and how it solves real-time problems in healthcare delivery.
- Integrity of Decision-making: Given the sizable contract and existing relationships with potential suppliers, the NHS must demonstrate a transparent, fair procurement process. Information should be provided about who makes decisions, how they are made, and how safeguards are in place to ensure fair competition.
- Relationship with the Supplier: The public needs assurance that NHS maintains control over the data and the system. This includes clarifying what data the supplier can access and the safeguards against misuse. Concerns about vendor lock-in and the ability for the NHS to terminate partnerships without compromising patient care or incurring significant costs should also be addressed.
In summary, the key to the FDP’s success lies in transparent, meaningful engagement with the public and healthcare professionals. Filling the existing knowledge gap with accurate information can quell mistrust and speculation, thereby earning public trust for a smoother implementation. Open communication, even when there are no complete answers, can prevent suspicion and ensure ongoing public support for the FDP initiative.
Share this story...
Real World Evidence (RWE) 201 – Beyond Clinical Trials: Health Canada’s Commitment to Real World Evidence
RWE 201 - Beyond Clinical Trials: Health Canada's Commitment to Real World Evidence Health Canada is dedicated to enhancing drug accessibility, affordability, and correct usage within the country. To [...]
Real World Evidence (RWE) 201 – A Tale of Two Regulatory Paths: Non-Interventional Studies in the USA
RWE 201 - A Tale of Two Regulatory Paths: Non-Interventional Studies in the USA Non-interventional studies are different from randomized controlled trials (RCTs). Instead of actively intervening in a [...]
Real World Evidence (RWE) 201 – FDA’s Advancing RWE Program
RWE 201 - FDA's Advancing RWE Program Real-world evidence is transforming the regulatory landscape, enabling the FDA to make informed decisions based on robust data from real-world settings. [...]
Real World Evidence (RWE) 201 – FDA’s RWE Considerations Draft Guidance
RWE 201 - FDA's RWE Considerations Draft Guidance The 21st Century Cures Act, signed into law in 2016, mandated the FDA to establish a framework for the evaluation of [...]
Real World Evidence 201 – FDAs RWE Framework
RWE 201 - FDAs RWE Framework Real World Evidence (RWE) 201 – FDAs RWE Framework RWE 201: https://rwr-regs.com/rwe-201/ The FDA's Real-World Evidence (RWE) Program framework, established under the [...]
Real World Evidence 201 – The 21st Century Cures Act
RWE 201 - The 21st Century Cures Act The 21st Century Cures Act (CURES 1.0), signed into law in the U.S. in December 2016, aimed to accelerate [...]







